<DOC>
	<DOC>NCT01209221</DOC>
	<brief_summary>This placebo-controlled, randomized, observer-blind, dose-ascending study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of RO5271983 in healthy volunteers. Healthy volunteers will be randomized to receive either a single oral dose of RO5271983 or placebo in the SAD part or multiple oral doses of RO5271983 or placebo in the MAD part. The anticipated time on study treatment is approximately 14 weeks for the SAD part and up to 8 weeks for the MAD part.</brief_summary>
	<brief_title>A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy volunteers, 1865 years of age Body Mass Index (BMI) between 18 and 32 kg/m2, inclusive In the SAD, females subjects must be surgically sterile or postmenopausal for the past year; in the MAD females may be of childbearing potential but must use 2 methods of highly effective contraception A history of clinically relevant cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurological, psychiatric, allergic or skin disease Clinical significant abnormalities in laboratory test results Symptoms of an infectious disease including upper respiratory tract infection within one month of study start or a history of recurrent infections Smokers of &gt;5 cigarettes/day within 3 months prior to admission and unable to stop smoking during study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>